ARTICLE | Product Development
Data from Regeneron, Agenus and others highlight immuno-oncology progress in genetically stable colorectal cancer at ASCO 2024
By Lauren Martz, Executive Director, Biopharma Intelligence
May 31, 2024 10:06 PM UTC
Several immuno-oncology mechanisms on display at ASCO 2024 help the field inch closer to solving one of cancer immunotherapy’s biggest problems: achieving efficacy in cold solid tumors.
These mechanisms include bispecific antibodies that engage multiple T cell activation signals, immunocytokine therapies that couple checkpoint inhibition with immune stimulating cytokines, and combinations of innate immune activators. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652573/immunotherapies-break-into-cold-colorectal-cancers-at-asco-2024